MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Parkinson’s"

  • 2023 International Congress

    Comparison of original and revised versions of the University of Pennsylvania Smell Identification Test

    M. Brumm, K. Pierz, W. Aamodt, C. Gochanour, R. Kurth, C. Coffey, T. Foroud, E. Brown, R. Doty, T. Simuni, C. Tanner, K. Marek, A. Siderowf (Iowa City, USA)

    Objective: To assess agreement between the original and revised versions of the University of Pennsylvania Smell Identification Test (UPSIT). Background: Recently published age/sex-specific UPSIT percentiles,…
  • 2023 International Congress

    Modeling Parkinson’s disease progression accounting for the effect of symptomatic treatments in the Parkinson’s Progression Markers Initiative study

    B. Ribba, T. Simuni, K. Marek, A. Siderowf, L. Chahine, C. Diack, A. Monnet, B. Ricci, T. Nikolcheva, G. Pagano (Basel, Switzerland)

    Objective: To explore the natural history of Parkinson’s disease (PD) accounting for the effect of symptomatic treatments on progression by modeling the time course of…
  • 2023 International Congress

    Preliminary results of the validation study of the Shame in Parkinson’s disease (SPARK) Scale

    I. Debove, C. Rodriguez-Blazquez, S. Murcia, A. Zenger, MM. Kurtis, E. Cubo, C. Falup-Pecurariu, KR. Chaudhuri, H. Reichman, S. Bostantjopoulou, M. Bereau, V. Fleury, P. Krack (Bern, Switzerland)

    Objective: The goal of this study is to validate the Shame in PARKinson’s disease (SPARK) Scale [1] which identifies the presence, the extent and some…
  • 2023 International Congress

    Artificial intelligence for the improvement of imaging biomarkers in Parkinson’s disease

    V. Dzialas, E. Doering, K. Simonyan, A. Strafella, D. Vaillancourt, T. van Eimeren (Cologne, Germany)

    Objective: To systematically review the current literature on the application of artificial intelligence (AI) for imaging biomarkers in Parkinson's disease (PD) and to identify translational…
  • 2023 International Congress

    Estimating the Incidence of Parkinson’s Disease in Patients with Epilepsy: A Nationwide Cohort Study in South Korea

    YS. Hwang, MG. Kang, MG. Lee, SW. Yeom, BS. Shin, JS. Kim, HG. Kang (Jeonju-si, Jeonbuk-do, Republic of Korea)

    Objective: We aimed to estimate the incidence of PD in patients with epilepsy and explore the association between epilepsy and PD. Background: Although epilepsy is…
  • 2023 International Congress

    Effect of Sex on the association between GBA mutations and Cognitive Decline in Parkinson’s Disease

    SP. Caminiti, M. Avenali, M. Inglese, C. Tassorelli, D. Perani (Pavia, Italy)

    Objective: To assess the impact of sex and glucocerebrosidase (GBA) mutations on cognitive trajectories in a sample of Parkinson's disease (PD) patients. Background: Accumulating evidence…
  • 2023 International Congress

    A Study to Evaluate the Efficacy and Safety of Intravenous Prasinezumab in Participants With Early Parkinson’s Disease (PADOVA): Rationale, Design, and Baseline Data

    T. Nikolcheva, G. Pagano, N. Pross, T. Simuni, K. Marek, R. Postuma, N. Pavese, F. Stocchi, K. Seppi, A. Monnet, N. Shariati, L. Rutten-Jacobs, S. Zanigni, T. Kustermann, K. Taylor, D. Trundell, H. Svoboda, A. Bonni, P. Fontoura, R. Doody (BASEL, Switzerland)

    Objective: The study will evaluate the efficacy and safety of prasinezumab in individuals with early-stage Parkinson's disease (PD) on stable symptomatic therapy. Background: Available treatments…
  • 2023 International Congress

    Effect and Mechanism of Shaoyao Gancao Decoction(SGD) in Treatment of Pain in Parkinson’s Disease Based on Network Pharmacology and Molecular Docking

    Q. Zhao (Shanghai, China)

    Objective: Based on the method of network pharmacology, this paper discusses the potential effects and mechanisms of SGD in the treatment of pain in PD. Background:…
  • 2023 International Congress

    Clinical-based diagnosis and self-reported Parkinson’s disease in a population-based sample in southern Brazil

    G. Pereira, N. Soares, G. Marconi, C. Sangali, I. Pasuch, C. Bertocchi, N. Bruscato, J. Senger, A. Schumacher-Schuh, C. Rieder (Porto Alegre, Brazil)

    Objective: To report the frequency of self-reported PD and the diagnostic evaluation performed by clinical neurologists in a population-based cohort from south Brazil. Background: It…
  • 2023 International Congress

    Transcranical Pulse Stimulation in Parkinson’s rest tremor: a pilot study.

    P. Manganotti, M. Liccari, TMI. Lombardo, M. Michelutti, M. Catalan (Trieste, Italy)

    Objective: The goal of this paper is to explore a possible effect of TPS on the PD rest tremor circuit, stimulating the motor cortex (M1)…
  • « Previous Page
  • 1
  • …
  • 115
  • 116
  • 117
  • 118
  • 119
  • …
  • 338
  • Next Page »

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Life expectancy with and without Parkinson’s disease in the general population
  • Nilotinib for treating MSA: A preclinical proof of concept study
  • An atypical and interesting feature of Parkinson´s disease
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • An atypical and interesting feature of Parkinson´s disease
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Patients with Essential Tremor Live Longer than their Relatives
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley